Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0GXYHR |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | SCAc-Met (1)xSCAc-Met (2) |
|||||
| Synonyms |
SCAc-Met (1)xSCAc-Met (2)
Click to Show/Hide
|
|||||
| Antigen Name | Hepatocyte growth factor receptor (MET) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CN117337196A Compound94 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive c-Met expression (c-Met+++/++) | ||
| Method Description |
c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 25% | Positive c-Met expression (c-Met+++/++) | ||
| Method Description |
c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 35% | Positive c-Met expression (c-Met+++/++) | ||
| Method Description |
c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 45% | Positive c-Met expression (c-Met+++/++) | ||
| Method Description |
c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||